Screening for depression in psoriasis patients during a dermatological consultation: A first step towards treatment.

Abstract

Depression is a highly prevalent comorbidity in psoriatic patients. The aim of this prospective study was to follow up psoriasis patients at risk for depression and to evaluate individual pathways to mental health care and the efficacy of depression screening in a real-life setting. In this prospective multicenter study, 355 patients with psoriasis were screened for depressive symptoms with the revised Beck Depression Inventory (BDI-II). General practitioners of patients at risk for depression were asked for further evaluation. One year later, information on mental health care provision was gathered. 130 patients were screened positive for depressive symptoms, and 71 patients were followed-up (follow-up rate: 54.6%). Psychiatric treatment was recommended for 28.2% and accepted by 23.9% of patients. Parameters of disease activity of psoriasis (PASI: 3.1, ∆: -1.7, P=0.018), quality of life (Dermatology Life Quality Index [DLQI]: 6.5, ∆: -2.8, P=0.005), and depressive symptoms (BDI-II: 13.2, ∆: -8.3, P<0.001) improved significantly. Decrease of the BDI-II score was more pronounced in patients with higher PASI decrease. Screening for depressive symptoms led to increased utilization of mental health care and improvement of psoriasis, depressive symptoms, and quality of life. Thus, such screening should be implemented in routine care to optimize patient management.